Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein

verfasst von: Yan Song, Xinjia Zhou, Weiliang Bai, Xiulan Ma

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

F-box/WD repeat-containing protein 7 (FBW7) is a member of the F-box protein family that regulates cell cycle progression and cell growth and differentiation. FBW7 also functions as a tumor suppressor. A cisplatin (CDDP)-based multidrug chemotherapy regimen is standard for nasopharyngeal carcinoma (NPC), but drug resistance is an increasing problem. Here, we evaluated the relationship between FBW7 and multidrug resistance-associated protein (MRP), and its correlation with drug resistance in NPC, and explored the mechanism underlying drug resistance to CDDP in this disease. We used cell viability assays, Western blotting, and small interfering RNA (siRNA) interference to investigate the underlying mechanism underlying CDDP resistance in a NPC cell line. The expression of FBW7 and MRP was detected by Western blotting after siRNA interference in the CDDP-resistant NPC cell line, CNE2-CDDP. The 3-(4 5-dimethyl-2-thiazolyl)-2 5-diphenyl-2-H-tetrazolium bromide (MTT) assay was used to evaluate drug sensitivity of various types of antitumor drugs, including paclitaxel (PCX), CDDP, fluorouracil (5-FU), and vincristine (VCR). We found that siRNA-mediated upregulation of FBW7 significantly increased CDDP chemosensitivity. The IC50 values of CDDP in siRNA-FBW7-CNE2-CDDP and FBW7-CNE2-CDDP-NC cells were 2.485 ± 0.155 and 4.867 ± 0.442 μmol/mL, respectively. The IC50 values of PCX, CDDP, 5-FU, and VCR were significantly decreased in siRNA-FBW7-CNE2 than in FBW7-CNE2-NC (3.46 ± 0.14 vs. 46.21 ± 6.03 μmol/mL; 3.76 ± 0.54 vs. 39.45 ± 0.96 μmol/mL; 2.14 ± 1.67 vs. 28.76 ± 1.89 μmol/mL; 4.43 ± 0.89 vs. 87.90 ± 3.45 μmol/mL, respectively). The IC50 of CDDP was significantly less in siRNA-FBW7-CNE2-CDDP than in FBW7-CNE2-CDDP-NC. The level of FBW7 expression in CNE2 cells was correlated with CDDP chemosensitivity. siRNA-mediated upregulation of FBW7 expression downregulated the expression of MRP, significantly increasing drug sensitivity in CNE2 cells.
Literatur
1.
Zurück zum Zitat Song Y, Yang J, Bai W-L, Ji W-Y. Anti-tumor and immunoregulatory effects of astragalus on nasopharyngeal carcinoma in vivo and in vitro. Phytother Res. 2011;25:909–15.CrossRefPubMed Song Y, Yang J, Bai W-L, Ji W-Y. Anti-tumor and immunoregulatory effects of astragalus on nasopharyngeal carcinoma in vivo and in vitro. Phytother Res. 2011;25:909–15.CrossRefPubMed
2.
Zurück zum Zitat Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104–11.CrossRefPubMed Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1104–11.CrossRefPubMed
3.
Zurück zum Zitat Wu Z, Li X, Zeng Y, et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol. 2011;108(3):177–84.CrossRefPubMed Wu Z, Li X, Zeng Y, et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol. 2011;108(3):177–84.CrossRefPubMed
4.
Zurück zum Zitat Yu H-G, Wei W, Xia L-H, Han W-L, Zhao P, Wu S-J, et al. FBW7 upregulation enhances cisplatin cytotoxicity in nonsmall cell lung cancer cells. Asian Pac J Cancer Prev. 2013;14:6321–6.CrossRefPubMed Yu H-G, Wei W, Xia L-H, Han W-L, Zhao P, Wu S-J, et al. FBW7 upregulation enhances cisplatin cytotoxicity in nonsmall cell lung cancer cells. Asian Pac J Cancer Prev. 2013;14:6321–6.CrossRefPubMed
5.
Zurück zum Zitat Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL 1 and FBW7. Nature. 2011;471:110–4.CrossRefPubMed Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL 1 and FBW7. Nature. 2011;471:110–4.CrossRefPubMed
6.
Zurück zum Zitat Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004;303:1374–8.CrossRefPubMed Nateri AS, Riera-Sans L, Da Costa C, Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science. 2004;303:1374–8.CrossRefPubMed
7.
Zurück zum Zitat Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67:9006–12.CrossRefPubMed Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 2007;67:9006–12.CrossRefPubMed
8.
Zurück zum Zitat O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24.CrossRefPubMedPubMedCentral O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007;204:1813–24.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Anzi S, Finkin S, Shaulian E. Transcriptional repression of c-Jun’s E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal. 2008;20:862–71.CrossRefPubMed Anzi S, Finkin S, Shaulian E. Transcriptional repression of c-Jun’s E3 ubiquitin ligases contributes to c-Jun induction by UV. Cell Signal. 2008;20:862–71.CrossRefPubMed
10.
Zurück zum Zitat Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182:19–26.CrossRefPubMedPubMedCentral Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. J Cell Biol. 2008;182:19–26.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, et al. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 2009;28:2393–405.CrossRefPubMed Kitagawa K, Hiramatsu Y, Uchida C, Isobe T, Hattori T, Oda T, et al. Fbw7 promotes ubiquitin-dependent degradation of c-Myb: involvement of GSK3-mediated phosphorylation of Thr-572 in mouse c-Myb. Oncogene. 2009;28:2393–405.CrossRefPubMed
12.
Zurück zum Zitat Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8(2):83–93.CrossRefPubMed Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8(2):83–93.CrossRefPubMed
13.
Zurück zum Zitat Minella AC, Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005;4(10):1356–9.CrossRefPubMed Minella AC, Clurman BE. Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005;4(10):1356–9.CrossRefPubMed
14.
Zurück zum Zitat Lau AW, Fukushima H, Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci. 2012;17:2197–212.CrossRef Lau AW, Fukushima H, Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci. 2012;17:2197–212.CrossRef
15.
Zurück zum Zitat Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2004;62:4535–9. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 2004;62:4535–9.
16.
Zurück zum Zitat Schülein-Völk C, Wolf E, Zhu J, Xu W, Taranets L, Hellmann A, et al. Dual regulation of fbw7 function and oncogenic transformation by usp28. Cell Rep. 2014;9(3):1099–109.CrossRefPubMed Schülein-Völk C, Wolf E, Zhu J, Xu W, Taranets L, Hellmann A, et al. Dual regulation of fbw7 function and oncogenic transformation by usp28. Cell Rep. 2014;9(3):1099–109.CrossRefPubMed
17.
Zurück zum Zitat Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH, et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012;586(10):1409–18.CrossRefPubMedPubMedCentral Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, Sarkar FH, et al. Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett. 2012;586(10):1409–18.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012;31(1–2):75–87.CrossRefPubMed Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012;31(1–2):75–87.CrossRefPubMed
19.
20.
Zurück zum Zitat Wang Z, Inuzuka H, Fukushima H, Wan L, Gao D, Shaik S, et al. Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep. 2012;13(1):36–43.CrossRef Wang Z, Inuzuka H, Fukushima H, Wan L, Gao D, Shaik S, et al. Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep. 2012;13(1):36–43.CrossRef
21.
Zurück zum Zitat Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003;163:1255–60.CrossRefPubMedPubMedCentral Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003;163:1255–60.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol. 2003;201:589–95.CrossRefPubMed Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol. 2003;201:589–95.CrossRefPubMed
23.
Zurück zum Zitat Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res. 2004;6:R531–9.CrossRefPubMedPubMedCentral Willmarth NE, Albertson DG, Ethier SP. Chromosomal instability and lack of cyclin E regulation in hCdc4 mutant human breast cancer cells. Breast Cancer Res. 2004;6:R531–9.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, et al. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol. 2005;98:124–8.CrossRefPubMed Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, et al. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol. 2005;98:124–8.CrossRefPubMed
25.
Zurück zum Zitat Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res. 2008;32:1751–5.CrossRefPubMed Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res. 2008;32:1751–5.CrossRefPubMed
26.
Zurück zum Zitat Jacob NK, Cooley JV, Shirai K. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther. 2012;5:7–20.CrossRefPubMedPubMedCentral Jacob NK, Cooley JV, Shirai K. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Onco Targets Ther. 2012;5:7–20.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Hu W, Ding W, Yang H, Shao M, Wang B, Wang J, et al. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiother Oncol. 2009;93(3):488–91.CrossRefPubMed Hu W, Ding W, Yang H, Shao M, Wang B, Wang J, et al. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiother Oncol. 2009;93(3):488–91.CrossRefPubMed
28.
Zurück zum Zitat Jiang D, Sui M, Zhong W, et al. Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells [J]. Cancer Lett. 2013;335(2):404–11.CrossRefPubMedPubMedCentral Jiang D, Sui M, Zhong W, et al. Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells [J]. Cancer Lett. 2013;335(2):404–11.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Jiang D, Sui M, Zhong W, Huang Y, Fan W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011;2:239–44.CrossRef Jiang D, Sui M, Zhong W, Huang Y, Fan W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011;2:239–44.CrossRef
30.
Zurück zum Zitat Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013;34(14):3626–38.CrossRefPubMed Zhou J, Zhao WY, Ma X, Ju RJ, Li XY, Li N, et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013;34(14):3626–38.CrossRefPubMed
31.
Zurück zum Zitat Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22(2):79–86.CrossRefPubMed Lo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22(2):79–86.CrossRefPubMed
32.
33.
Zurück zum Zitat Tebra S, Kallel A, Boussen H, Bouaouina N. Medical treatment of nasopharyngeal cancers. Tunis Med. 2011;89(4):326–31.PubMed Tebra S, Kallel A, Boussen H, Bouaouina N. Medical treatment of nasopharyngeal cancers. Tunis Med. 2011;89(4):326–31.PubMed
34.
Zurück zum Zitat Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29–46.CrossRefPubMed Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov. 2011;10:29–46.CrossRefPubMed
35.
Zurück zum Zitat Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol. 2011;12:605–20.CrossRefPubMedPubMedCentral Weissman AM, Shabek N, Ciechanover A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nat Rev Mol Cell Biol. 2011;12:605–20.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM. Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 2011;112:3882–90.CrossRefPubMedPubMedCentral Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM. Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway during hypoxia. J Cell Biochem. 2011;112:3882–90.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Fruh M. The search for improved systemic therapy of non-small cell lung cancer—what are today’s options? Lung Cancer. 2011;72:265–70.CrossRefPubMed Fruh M. The search for improved systemic therapy of non-small cell lung cancer—what are today’s options? Lung Cancer. 2011;72:265–70.CrossRefPubMed
38.
Zurück zum Zitat Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, Suzuki S, Nakamura S, et al. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div. 2010;5:27.CrossRefPubMedPubMedCentral Kitagawa K, Kotake Y, Hiramatsu Y, Liu N, Suzuki S, Nakamura S, et al. GSK3 regulates the expressions of human and mouse c-Myb via different mechanisms. Cell Div. 2010;5:27.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104–9.CrossRefPubMedPubMedCentral Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471:104–9.CrossRefPubMedPubMedCentral
Metadaten
Titel
FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein
verfasst von
Yan Song
Xinjia Zhou
Weiliang Bai
Xiulan Ma
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3056-4

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.